Home Cart Sign in  
Chemical Structure| 420831-40-9 Chemical Structure| 420831-40-9

Structure of AK-7
CAS No.: 420831-40-9

Chemical Structure| 420831-40-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AK-7 is a cell-permeable and blood-brain barrier-penetrable SIRT2 inhibitor with an IC50 of 15.5 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AK-7

CAS No. :420831-40-9
Formula : C19H21BrN2O3S
M.W : 437.35
SMILES Code : O=C(NC1=CC=CC(Br)=C1)C2=CC=CC(S(=O)(N3CCCCCC3)=O)=C2
MDL No. :MFCD03140195
InChI Key :IYAYHZZWYNXHEQ-UHFFFAOYSA-N
Pubchem ID :1328033

Safety of AK-7

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H319
Precautionary Statements:P305+P351+P338

Related Pathways of AK-7

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 10 μM 24 hours Study the effect of AK-7 on P38 acetylation level PMC7736920
RAW 264.7 cells 25 µM 20 hours To investigate the effect of SIRT2 inhibitor AK-7 on autophagy regulation in tolerant cells, results showed that AK-7 treatment increased beclin-1 and LC3b-II expression and reduced p62 accumulation. PMC8066127
Human ovarian teratocarcinoma (PA-1) cell line 12.5, 25, 50, 100, 200 µg/mL 24 hours To evaluate the cytotoxic effect of AK-7 extract on the PA-1 cell line. Results showed a significant decrease in cell viability of the PA-1 cell line with increasing concentrations of AK-7 extract, with an IC50 value of 82.04 µg/mL. PMC10609037
CD4+ T cells 0.1–10 μM 3 days AK-7 increased the percentage of IL-2-producing CD4+ T cells in a dose-dependent manner. PMC9151795
Th17 cells 0.1–10 μM 3 days AK-7 significantly reduced the differentiation of Th17 cells in a dose-dependent manner but did not affect the differentiation of Th1, Th2, or Treg cells or cell viability. PMC9151795
Neural stem/progenitor cells (NSPCs) 10 μM every 3 days To validate the inhibitory effect of AK-7 on ODEXs-promoted neurogenesis and synaptic protein expression PMC10912796
Primary mesencephalic neuron/glia cultures 25 µM To investigate the protective effect of AK-7 on dopaminergic neurons, results showed AK-7 significantly increased TH-IR cell counts PMC4466888

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Autoimmune encephalomyelitis (EAE) model Intraperitoneal injection 20 mg/kg Daily from 8 weeks of age to 16 weeks of age AK-7 treatment significantly improved clinical scores and body weight loss in EAE mice, reduced the number of spinal cord-infiltrating CD4+ T cells and IL-17A-producing CD4+ T cells. PMC9151795
Mice Huntington's disease Mice models Intraperitoneal injection 10, 20, and 30 mg/kg Twice daily, starting from 4 weeks of age AK-7 treatment significantly improved motor function, extended survival, and reduced brain atrophy and mutant huntingtin aggregation in R6/2 and 140CAG mice. PMC3534897
Rats Aging rats with increased neonatal iron intake Intranigral injections 5 μg/side per day Administered at postnatal days 540 and 570 AK-7 significantly diminished striatal dopamine depletion and improved behavior abnormalities PMC4281432
Rats Aging rats with increased neonatal iron intake Intranigral injections 5 μg/side per day Injected at postnatal days 540 and 570 AK-7 significantly diminished striatal dopamine depletion and improved behavior abnormality PMC4281432
C57BL/6J mice Chronic unpredictable mild stress (CUMS)-induced depression model Intraperitoneal injection 20 mg/kg Once daily for 2 weeks Blocking SIRT2 reverses the antidepressant effects of ODEXs PMC10912796
Sprague-Dawley rats Hypoxic-ischemic white matter damage model Intraperitoneal injection 20 mg/kg Once daily for 5 consecutive days AK-7 inhibited SIRT2 activity, reversing the protective effects of caffeine on hypoxic-ischemic white matter damage, as evidenced by reduced expression of myelinating and synaptic proteins. PMC9160447
Sprague-Dawley rats Aging-related Parkinson's disease model Intranigral injection 1 µg/day/side or 5 µg/day/side Administered on the first and eighth day of rotenone treatment To investigate the protective effect of AK-7 on behavioral abnormalities and striatal dopamine depletion in aging rats, results showed AK-7 significantly improved behavioral abnormalities and striatal dopamine depletion PMC4466888

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.43mL

2.29mL

1.14mL

22.86mL

4.57mL

2.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories